Novartis’ Sandoz division has announced a new UK headquarters based in Camberley, Surrey.
The global leader in generics and biosimilars announced that it has opened the new building at Watchmoor Park, forming part of the company’s “Transforming Sandoz” strategy, which aims to enable the business to “strengthen its role as a leading provider of medicines to the NHS.”
The company says that the site will be the centre of its UK operations, which encompasses a range of operational functions. It also announced that it is “are hugely excited” to be opening the “new home”, and that “The move is part of our mission to build a long-term future in the UK and to continue working with the NHS to ensure access to generic medicines and biosimilars” said Timothy de Gavre, Sandoz UK country head.
He continued, “Watchmoor Park is the right home for us and our customers; offering convenience, an ideal location and appropriate facilities for our business requirements. As a company, we are on an exciting journey and we look forward to supporting the progress of Watchmoor Park as a thriving
By Anna Smith
Thermo Fisher Scientific has acquired Novasep’s viral vector manufacturing business in Belgium, Henogen, for about €725m ($874.5m) in cash. Henogen offers biotechnology firms, as well as biopharma customers contract manufacturing services for vaccines and therapies.
Research and development group of Eli Lilly and Company, Loxo Oncology at Lilly, and clinical-stage oncology company Merus have announced a research collaboration and exclusive license agreement to develop T-Cell re-directing bispecific antibodies.
Chinese cancer biotech Adagene has filed to raise up to $125 million in a Nasdaq IPO. The listing will give Adagene the means to run early-phase clinical trials of antibodies against CD137 and CTLA-4.